French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...

Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, today announced ...

CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced its financial results for the ...

We will begin the MacroGenics 2024 third-quarter corporate progress and financial results conference call in just a moment.

The Company presented interim results from the TAMARACK study at the European Society for Medical Oncology (ESMO) Congress in September 2024 and expects to have mature median radiographic ...

Multinational pharmaceutical and medical equipment companies will bring a variety of innovative medical solutions that ...

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that TZIELD, vobramitamab duocarmazine ...

Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, ...

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that TZIELD, vobramitamab duocarmazine ...

Tzield sales were €15 million in the quarter, compared with €11 million in the previous quarter. Tzield, approved to delay the onset of type I diabetes, was added to Sanofi’s portfolio with ...

They were driven by new pharmaceutical launches (up 67.1% to €727 million), including Altuviiio, used to treat haemophilia, Tzield - for type 1 diabetes -, Sarclisa (multiple myeloma) and Rezurock, ...

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that TZIELD, vobramitamab duocarmazine ...